IR-Med, Inc. 8-K

What Happened

• IR-Med, Inc. (IRME) filed a Form 8-K reporting two material events in early February 2026. On February 3, 2026, CEO Ran Ziskind resigned effective immediately, citing disagreements over strategic direction, management approach, and certain employment matters.
• On February 4, 2026 the company entered a Securities Purchase Agreement and completed a private placement that closed on February 5, 2026, raising aggregate gross proceeds of $43,619. The Offering issued 14,070,644 shares of common stock at $0.0031 per share and warrants to purchase up to 7,035,322 additional shares at an exercise price of $0.03 per share. The warrants are exercisable immediately and have a five‑year term (per the agreement).

Key Details

• Total raised: $43,619 in gross proceeds from the private placement.
• Securities issued: 14,070,644 common shares at $0.0031 each and warrants for 7,035,322 shares (exercise price $0.03; five‑year term; exercisable immediately).
• Directors participated as investors and provided all proceeds: Oded Bashan purchased 10,422,580 shares + 5,211,290 warrants ($32,310); Yaniv Cohen, Yechiel Even and Ron Mayron each purchased 1,042,258 shares + 521,129 warrants ($3,231 each); Aharon Klein purchased 521,290 shares + 260,645 warrants ($1,616).
• The securities were sold in a private placement exempt from SEC registration (Section 4(a)(2), Rule 506(b), and Regulation S for non‑U.S. investors) and are unregistered for resale in the U.S.

Why It Matters

• Leadership: The immediate resignation of the CEO is a material governance change that may affect company strategy and operations; investors should watch for announcements about an interim or replacement CEO.
• Dilution and financing: Although the capital raised is modest ($43.6K), the company issued a large number of shares at a low price and issued warrants that could further dilute existing shareholders if exercised.
• Insider support: Directors funded the entire placement, which signals board-level support for the financing but also concentrates new holdings with insiders.
• Next steps: Investors should monitor IR-Med’s filings for details on CEO succession, any related employment arrangements, and further disclosures about use of proceeds or additional financings.